NSG mice co-implanted with human PBMC and NCI-H929 or MOLP-8 myeloma xenografts
“In vivo studies were performed to evaluate the anti-tumor efficacy and minimum effective dose of linvoseltamab in immunodeficient NSG mice SC co-implanted with human PBMC and either NCI-H929 (BCMA-high) or MOLP-8 (BCMA-low) MM cells.”
✓ VerifiedFDA multi-discipline review, p. 74Source ↗
Why that model
Binds human and cynomolgus monkey BCMA but not rat or mouse BCMA
“Overall, data indicate that linvoseltamab bound human and Cynomolgus monkey BCMA, but not rat or mouse BCMA.”